International Survey Exposes Inconsistencies in Bone Health Testing Across Laboratories Worldwide
A global survey of 231 laboratories across 41 countries identified substantial variations in how bone status biomarkers are measured, including differences in equipment, specimen handling, reporting units, and reference ranges. The study found inconsistent adoption of specific bone metabolism tests and variable participation in quality assurance programs, which undermines the ability to compare results across institutions. These inconsistencies hinder clinical decision-making and prevent meaningful data sharing among healthcare providers internationally.
The International Osteoporosis Foundation and International Federation of Clinical Chemistry collaborated on research involving nearly a quarter thousand laboratories spanning multiple continents. Their investigation documented how bone metabolism measurements differ fundamentally depending on where testing occurs—from the physical equipment used to process samples, through to how results get communicated numerically and interpreted clinically. Some diagnostic markers show particularly troubling gaps, with certain bone-specific tests remaining unavailable in many regions while others rely on outdated measurement technologies.
The standardization effort addresses a two-decade advocacy campaign by these organizations. Bone status biomarkers serve as diagnostic complements to imaging techniques, offering insights into metabolic activity and how patients respond to treatments. Without consistent measurement protocols globally, identical patient samples could yield substantially different numerical results across institutions, creating confusion for clinicians attempting to monitor disease progression or evaluate therapeutic effectiveness across different healthcare systems.
Fragmented laboratory practices could impede clinical outcomes for patients with bone disorders, potentially affecting diagnosis accuracy and treatment monitoring internationally. Healthcare providers relying on results from different labs may struggle to make comparable assessments, particularly for conditions like osteoporosis requiring long-term management. Standardization efforts may benefit pharmaceutical development and multi-center research by enabling reliable data consolidation, though achieving global laboratory harmonization requires coordinated adoption of new protocols among institutions with varying resources and existing infrastructure.